|Publication number||US20050149146 A1|
|Application number||US 11/047,137|
|Publication date||Jul 7, 2005|
|Filing date||Jan 31, 2005|
|Priority date||May 9, 2002|
|Also published as||US7076307, US20050004621, US20050131486, US20050131487, US20050143787|
|Publication number||047137, 11047137, US 2005/0149146 A1, US 2005/149146 A1, US 20050149146 A1, US 20050149146A1, US 2005149146 A1, US 2005149146A1, US-A1-20050149146, US-A1-2005149146, US2005/0149146A1, US2005/149146A1, US20050149146 A1, US20050149146A1, US2005149146 A1, US2005149146A1|
|Inventors||Birinder Boveja, Angely Widhany|
|Original Assignee||Boveja Birinder R., Angely Widhany|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (19), Referenced by (95), Classifications (23), Legal Events (1)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a continuation of application Ser. No. 11/035,374 filed Jan. 13, 2005, entitled “Method and system for providing electrical pulses for neuromodulation of vagus nerve(s) using rechargeable implanted pulse generator”, which is a continuation of application Ser. No. 10/841,995 filed May 8, 2004, which is a continuation of application Ser. No. 10/196,533 filed Jul. 16, 2002, which is a continuation of application Ser. No. 10/142,298 filed on May 9, 2002. The prior applications being incorporated herein in entirety by reference, and priority is claimed from these applications.
This invention relates generally to electrical stimulation therapy for medical disorders, more specifically to providing electrical pulses for neuromodulation therapy for obesity and other medical disorders, by selectively modulating sympathetic nervous system with rechargeable implantable pulse generator.
Obesity is a significant health problem in the United States and many other developed countries. Obesity results from excessive accumulation of fat in the body. It is caused by ingestion of greater amounts of food than can be used by the body for energy. The excess food, whether fats, carbohydrates, or proteins, is then stored almost entirely as fat in the adipose tissue, to be used later for energy. Obesity is not simply the result of gluttony and a lack of willpower. Rather, each individual inherits a set of genes that control appetiete and metabolism, and a genetic tendency to gain weight that may be exacerbated by environmental conditions such as food availability, level of physical activity and individual psychology and culture. Other causes of obesity include psychogenic, neurogenic, and other metabolic related factors.
Obesity is defined in terms of body mass index (BMI), which provides an index of the relationship between weight and height. The BMI is calculated as weight (in Kilograms) divided by height (in square meters), or as weight (in pounds) times 703 divided by height (in square inches). The primary classification of overweight and obesity relates to the BMI and the risk of mortality. Obesity has reached epidemic proportions globally. In the U.S., it is estimated that 64% of adults are overweight or obese, and 4.7% or 14-16 million Americans are morbidly obese (BMI≦40 Kg/m2). Furthermore, the number of overweight adolescents is also rapidly increasing.
Treatment of obesity depends on decreasing energy input below energy expenditure. Treatment has included among other things various drugs, starvation and even stapling or surgical resection of a portion of the stomach. Surgery for obesity has included gastroplasty and gastric bypass procedure. Gastroplasty which is also known as stomach stapling, involves constructing a 15- to 30 mL pouch along the lesser curvature of the stomach. A modification of this procedure involves the use of an adjustable band that wraps around the proximal stomach to create a small pouch. Both gastroplasty and gastric bypass procedures have a number of complications.
Advantageously, electrical pulse therapy can be safely provided by delivering electrical pulses to the parasympathetic nerves such as the vagus nerve(s) or the sympathetic nerves such as the splanchnic nerves (or greater splanchnic nerve).
In commonly assigned disclosures Ser. No. 10,079,21 now U.S. Pat. No. ______, and U.S. Pat. No. 6,611,715 B1 (Boveja) electrical pulsed neuromodulation therapy for obesity and other medical conditions is provided by delivering electrical pulses to the parasympathetic nerves such as the vagus nerve(s). Therapeutic effects on obesity may also be achieved by providing electrical pulses (or modulating) the sympathetic nervous system. The apparatus disclosed in U.S. Pat. No. 6,611,715 B1 (Boveja) can also be used in neuromodulating the sympathetic nervous system, of course the stimulating electrodes would by placed on the splanchnic nerves or celiac ganglia (as shown in
The rationale for this is shown in conjunction with
In the Applicant's U.S. Pat. No. 6,611,715 B1 electrical pulses are provided to the vagal pathway as shown in conjunction with
Shown in conjunction with
The gastrointestinal tract has a nervous system all its own called the enteric nervous system 20. This is shown in conjunction with
As depicted in conjunction with
Sympathetic innervation of the gastrointestinal (GI) tract is mainly via postganglionic adrenergic fibers whose cell bodies are located in pre-vertebral and parabertabral ganglia. The celiac, superior and inferior mesenteric, and hypogastric plexus provide sympathetic innervation to various segments of the GI tract. Activation of the sympathetic nerves usually inhibits the motor and secretory activities of the GI system.
Parasympathetic innervation of the GI tract down to the level of the transverse colon is provided by branches of the vagus nerves (10th cranial nerve). Excitation of parasympathetic nerves usually stimulates the motor and secretory activities of the GI tract.
Additionally in terms of reflex control, shown in conjunction with
The stomach 5 (shown in
Parasympathetic innervation to the stomach 5 is also supplied by the vagus nerves, while sympathetic innervation to the stomach is provided by the celiac plexus. In general, parasympathetic nerves stimulate gastric smooth muscle motility and gastric secretions, whereas sympathetic activity inhibits these-function. Numerous sensory afferent fibers leave the stomach in the vagus nerves; some of these fibers travel with sympathetic nerves. Other sensory neurons are the afferent links between sensory receptors and the intramural plexuses of the stomach. Some of these afferent fibers relay information intragastric pressure, gastric distention, intragastric pH, or pain.
When a wave of esophageal peristalsis begins, a reflex causes the LES to relax. This relaxation of the LES is followed by receptive relaxation of the fundus and body of the stomach 5. The stomach 5 will also relax if it is filled directly with gas or liquid. The nerve fibers in the vagi are a major efferent pathways for reflex relaxation the stomach 5.
The emptying of gastric contents is regulated by both neural and hormonal mechanisms. The duodenal and jejunal mucosa contain receptors that sense acidity, osmotic pressure, certain fats and fat digestion products, and peptides and amino acids This is depicted in
Shown in conjunction with
In most other excitable tissues, the resting membrane potential remians rather constant. In gastrointestinal smooth muscle, the resting membrane potential characteristically varies or oscillates, this is depicted in
Slow waves are generated by interstitial cells. These cells are located in a thin layer between the longitudinal and circular layers of the muscularis externa. Interstitial cells have properties of both fibroblasts and smooth muscle cells. Their long processes form gap junction with longitudinal and circular smooth muscle cells. These gap junctions enable the slow waves to be conducted rapidly to-both muscle layers. Because gap junctions electrically couple the smooth muscle cells of both longitudinal and circular layers, the slow wave spreads throughout the smooth muscle of each segment of the gastrointestinal tract.
The amplitude and, to a lesser extent, the frequency, of the slow waves can be modulated by the activity of intrinsic and extrinsic nerves and by hormones and paracrine substanes. In general, sympathetic nerve activity decreases the amplitude of the slow waves or ablolshes them completely, wheras stimulation of parasympathetic nerves increases the size of the slow waves.
If the peak of the slow wave exceeds the cell's threshold to fire action potentials, one or more action potentials may be triggered during the peak of the slow wave (
Action potentials: Action potentials in gastrointestinal smooth muscle are more prolonged (10 to 20 msec) than those of skeletal muscle and have little or no overshoot. The rising phase of the action potentials is caused by ion flow through channels that conduct both Ca++ and Na+ and are relatively slow to open. Ca++ that enters the cell during the action potential helps to initiate contraction.
When the membrane potential of gastrointestinal smooth muscle reaches the electrical threshold, typically near the peak of a slow wave, a train of action potentials (1 to 10/sec) is fired (
Slow waves that are not accompanied by action potentials elicit weak contractions of the smooth muscle cells (
Between trains of action potentials the tension developed by gastrointestinal smooth muscle falls, but not to zero. This nonzero resting, or baseline, tension of smooth muscle is the tone. The tone of gastrointestinal smooth muscle is altered by neuroeffectors, hormones, paracrine substances, and drugs.
Control of the contractile and secretory activities of the gastrointestinal tract involves the central nervous system, the enteric nervous system, and hormones and paracrine substances. The autonomic nervous system typically only modulates the patterns of muscular and secretory activity; these activities are controlled more directly by the enteric nervous system.
Shown in conjunction with
Most nerves in the human body are composed of thousands of fibers of different sizes. This is shown schematically in
In a cross section of peripheral nerve it is seen that the diameter of individual fibers vary substantially, as is also shown schematically in
The diameters of group A and group B fibers include the thickness of the myelin sheaths. Group A is further subdivided into alpha, beta, gamma, and delta fibers in decreasing order of size. There is some overlapping of the diameters of the A, B, and C groups because physiological properties, especially in the form of the action potential, are taken into consideration when defining the groups. The smallest fibers (group C) are unmyelinated and have the slowest conduction rate, whereas the myelinated fibers of group B and group A exhibit rates of conduction that progressively increase with diameter.
Nerve cells have membranes that are composed of lipids and proteins, and have unique properties of excitability such that an adequate disturbance of the cell's resting potential can trigger a sudden change in the membrane conductance. Under resting conditions, the inside of the nerve cell is approximately −90 mV relative to the outside. The electrical signaling capabilities of neurons are based on ionic concentration gradients between the intracellular and extracellular compartments. The cell membrane is a complex of a bilayer of lipid molecules with an assortment of protein molecules embedded in it, separating these two compartments. Electrical balance is provided by concentration gradients which are maintained by a combination of selective permeability characteristics and active pumping mechanism.
A nerve cell can be excited by increasing the electrical charge within the neuron, thus increasing the membrane potential inside the nerve with respect to the surrounding extracellular fluid. The threshold stimulus intensity is the value at which the net inward current (which is largely determined by Sodium ions) is just greater than the net outward current (which is largely carried by Potassium ions), and is typically around −55 mV inside the nerve cell relative to the outside (critical firing threshold). If however, the threshold is not reached, the graded depolarization will not generate an action potential and the signal will not be propagated along the axon. This fundamental feature of the nervous system i.e., its ability to generate and conduct electrical impulses, can take the form of action potentials, which are defined as a single electrical impulse passing down an axon. This action potential (nerve impulse or spike) is an “all or nothing” phenomenon, that is to say once the threshold stimulus intensity is reached, an action potential will be generated.
To stimulate an excitable cell, it is only necessary to reduce the transmembrane potential by a critical amount. When the membrane potential is reduced by an amount ΔV, reaching the critical or threshold potential. When the threshold potential is reached, a regenerative process takes place: sodium ions enter the cell, potassium ions exit the cell, and the transmembrane potential falls to zero (depolarizes), reverses slightly, and then recovers or repolarizes to the resting membrane potential (RMP). For a stimulus to be effective in producing an excitation, it must have an abrupt onset, be intense enough, and last long enough.
Cell membranes can be reasonably well represented by a capacitance C, shunted by a resistance R as shown by an electrical model in
When the stimulation pulse is strong enough, an action potential will be generated and propagated. As shown in
A single electrical impulse passing down an axon is shown schematically in
The information in the nervous system is coded by frequency of firing rather than the size of the action potential. In terms of electrical conduction, myelinated fibers conduct faster, are typically larger, have very low stimulation thresholds, and exhibit a particular strength-duration curve or respond to a specific pulse width versus amplitude for stimulation, compared to unmyelinated fibers. The A and B fibers can be stimulated with relatively narrow pulse widths, from 50 to 200 microseconds (μs), for example. The A fiber conducts slightly faster than the B fiber and has a slightly lower threshold. The C fibers are very small, conduct electrical signals very slowly, and have high stimulation thresholds typically requiring a wider pulse width (300-1,000 μs) and a higher amplitude for activation. Because of their very slow conduction, C fibers would not be highly responsive to rapid stimulation. Selective stimulation of only A and B fibers is readily accomplished. The requirement of a larger and wider pulse to stimulate the C fibers, however, makes selective stimulation of only C fibers, to the exclusion of the A and B fibers, virtually unachievable inasmuch as the large signal will tend to activate the A and B fibers to some extent as well.
As shown in
TABLE 1 Conduction Fiber Fiber Velocity Diameter Type (m/sec) (μm) Myelination A Fibers Alpha 70-120 12-20 Yes Beta 40-70 5-12 Yes Gamma 10-50 3-6 Yes Delta 6-30 2-5 Yes B Fibers 5-15 <3 Yes C Fibers 0.5-2.0 0.4-1.2 No
In the methodology of the current disclosure, it will usually be desired to stimulate the A-fibers and B-fibers and not the c-fibers (since the c-fibers carry pain). Advantageously, this can be readily accomplished using the system and methodology of the current disclosure.
This application is also related to co-pending applications entitled “METHOD AND SYSTEM FOR VAGAL BLOCKING WITH OR WITHOUT VAGAL STIMULATION TO PROVIDE THERAPY FOR OBESITY AND OTHER GASRTOINTESTINAL DISORDERS USING RECHARGEABLE IMPLANTED PULSE GENERATOR” and “METHOD AND SYSTEM FOR PROVIDING ELECTRICAL PULSES TO GASTRIC WALL OF A PATIENT WITH RECHARGEABLE IMPLANTABLE PULSE GENERATOR FOR TREATING OR CONTROLLING OBESITY AND EATING DISORDERS.
Prior art is generally directed to adapting cardiac pacemaker technology for nerve stimulation, where U.S. Pat. Nos. 5,263,480 (Wernicke et al.) and 5,188,104 (Wernicke et al.) are generally directed to treatment of eating disorders with vagus nerve stimulation using an implantable neurocybernetic prosthesis (NCP), which is a “cardiac pacemaker-like” device. There is no disclosure for vagal blocking, sympathetic stimulation, or for using a rechargeable implantable device.
U.S. Pat. No. 5,540,730 (Terry et al.) is generally directed to treating motility disorders with vagus nerve stimulation using an implantable neurocybernetic prosthesis (NCP), which is a “cardiac pacemaker-like” device.
U.S. Pat. No. 6,611,715 B1 (Boveja) is generally directed to a system and method to provide therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator.
U.S. Pat. No. 6,553,263B1 (Meadows et al.) is generally directed to an implantable pulse generator system for spinal cord stimulation, which includes a rechargeable battery. In the Meadows '263 patent there is no disclosure or suggestion for combing a stimulus-receiver module to an implantable pulse generator (IPG) for use with an external stimulator, for providing modulating pulses to sympathetic nerve(s), as in the applicant's disclosure.
U.S. Pat. No. 6,505,077 B1 (Kast et al.) is directed to electrical connection for external recharging coil. In the Kast '077 disclosure, a magnetic shield is required between the externalized coil and the pulse generator case. In one embodiment of the applicant's disclosure, the externalized coil is wrapped around the pulse generator case, without requiring a magnetic shield.
U.S. Pat. No. 6,622,041 B2 (Terry, Jr. et al.) is directed to treatment of congestive heart failure and autonomic cardiovascular drive disorders using implantable neurostimulator.
The method and system of the current invention overcomes many shortcomings of the prior art by providing method and system for neuromodulation with extended power source either in the form of rechargeable battery, or by utilizing an external stimulator in conjunction with an implanted pulse generator device, to provide therapy for obesity, eating disorders or for inducing weight loss.
Accordingly, in one aspect of the invention, electrical pulses are provided to sympathetic nerves utilizing a rechargeable implantable pulse generator.
In another aspect of the invention, the electrical pulses are provided to at least one of splanchnic nerve, the greater splanchnic nerve, celiac ganglia or other portion of sympathetic nerve plexus in the gastric region or their branch(s) or part thereof.
In another aspect of the invention, the pulse amplitude delivered to sympathetic nervous system can range from 0.25 volt to 15 volts.
In another aspect of the invention, the pulse width of electrical pulses delivered can range from 20 micro-seconds to 5 milli-seconds.
In another aspect of the invention, the frequency of electrical pulses delivered to sympathetic nervous system can range from 5 cycle/second to 200 cycles/second.
In another aspect of the invention, a coil used in recharging said pulse generator is around the implantable pulse generator case, in a silicone enclosure.
In another aspect of the invention, the rechargeable implanted pulse generator comprises two feedthroughs.
In another aspect of the invention, the rechargeable implanted pulse generator comprises only one feedthrough for externalizing the recharge coil.
In another aspect of the invention, the implantable rechargeable pulse generator comprises stimulus-receiver means such that, the implantable rechargeable pulse generator can function in conjunction with an external stimulator, to provide the stimulation and/or blocking pulses to sympathetic nervous system.
In another aspect of the invention, the rechargeable battery comprises at least one of lithium-ion, lithium-ion polymer batteries.
In another aspect of the invention, the external programmer or the external stimulator comprises networking capabilities for remote communications over a wide area network for remote interrogation and/or remote programming.
In yet another aspect of the invention, the implanted lead comprises at least one electrode(s) which is/are made of a material selected from the group consisting of platinum, platinum/iridium alloy, platinum/iridium alloy coated with titanium nitride, and carbon.
This and other objects are provided by one or more of the embodiments described below.
For the purpose of illustrating the invention, there are shown in accompanying drawing forms which are presently preferred, it being understood that the invention is not intended to be limited to the precise arrangement and instrumentalities shown.
In the method and system of this invention, the rechargeable implantable pulse generator (RIPG) system, including a lead comprising at least one electrode(s) is/are implanted in the body. The electrode(s) are adapted to make contact with the nerve tissue where the electrical pulses are to be provided. In one embodiment, the electrode(s) may wrap around the nerve tissue to be stimulated (or blocked). Additional electrode(s) may be placed for the purpose of providing blocking pulses. The electrode(s) may be placed using laproscopic surgery, or alternatively surgical incision may be performed for wider exposure of the tissues. The tissue to be stimulated (or blocked) is identified, which is preferably the greater splanchnic nerve 54 or branches, or the tissue around the celiac ganglion 55, or any plexus in the region. Other sites in the region may also be identified for modulation of sympathetic system to provide therapy for obesity. Modulation in this patent disclosure implies any stimulation, blocking, selective stimulation, and selective stimulation of a portion in combination with selective blocking of a portion of the nervous system.
Once the appropriate electrode(s) is/are positioned and attached (shown in conjunction with
Shown in conjunction with
The pulses are provided to the cathode 61 with the return being anode 62 for bipolar mode of stimulation. For unipolar mode of stimulation the pulse generator case acts as the anode (i.e. the return electrode). Switching of stimulation pulses from bipolar mode to unipolar mode is a programmable parameter, and may be performed with the programmer. Bipolar stimulation offers localized stimulation of tissue compared to unipolar stimulation. For the practice of this invention, unipolar mode of stimulation would also have certain advantages such as stimulating an area of tissue comprising ganglion or nerve plexus.
The selective stimulation and/or blocking to the sympathetic nervous tissue can be performed in one of two ways. One method is to activate one of the “pre-determined” programs from the memory. A second method is to “custom” program the electrical parameters which can be selectively programmed, for specific therapy to the individual patient. Additionally, a program may be selected from memory, and selected parameters may be adjusted or “fine-tuned”. The electrical parameters which can be individually programmed, include variables such as pulse amplitude, pulse width, frequency of stimulation, type of pulse (e.g. blocking pulses may be sinusoidal), stimulation on-time, and stimulation off-time. Table two below defines the approximate range of parameters,
TABLE 2 Electrical parameter range delivered to the nerve for stimulation and/or blocking PARAMER RANGE Pulse Amplitude 0.1 Volt-15 Volts Pulse width 20 μS-5 mSec. Stim. Frequency 5 Hz-200 Hz Freq. for blocking DC to 5,000 Hz On-time 5 Secs-24 hours Off-time 5 Secs-24 hours
The implanted lead component of the system is somewhat similar to cardiac pacemaker leads, except for distal portion 40 (or electrode end) of the lead. The lead terminal preferably is linear, even though it can be bifurcated, and plug(s) into the cavity of the pulse generator means. The lead materials are described later in this disclosure.
Shown in conjunction with
The pulses delivered to the nerve tissue for stimulation therapy are shown graphically in
Because of the rapidity of the pulses required for modulating nerve tissue 54 (unlike cardiac pacing), there is a real need for power sources that will provide an acceptable service life under conditions of continuous delivery of high frequency pulses.
For the practice of the current invention, two embodiments of implantable pulse generators may be used. Both embodiments comprise re-chargeable power sources, such as Lithium-ion polymer battery.
In one embodiment, the implanted device comprises a stimulus-receiver module and a pulse generator module. Advantageously, this embodiment provides an ideal power source, since the power source can be an external stimulator coupled with an implanted stimulus-receiver, or the power source can be from the implanted rechargeable battery. Shown in conjunction with
In this embodiment, as shown in
The system of this embodiment provides a power sense circuit 728 that senses the presence of external power communicated with the power control 730, when adequate and stable power is available from an external source. The power control circuit controls a switch 736 that selects either implanted battery power 740 or conditioned external power from 726. The logic and control section 732 and memory 744 includes the IPG's microcontroller, pre-programmed instructions, and stored changeable parameters. Using input for the telemetry circuit 742 and power control 730, this section controls the output circuit 734 that generates the output pulses.
Shown in conjunction with
The stimulus-receiver portion of the circuitry is shown in conjunction with
As shown in conjunction with
In one embodiment, the coil may also be positioned on the titanium case as shown in conjunction with
A schematic diagram of the implanted pulse generator (IPG 391R), with re-chargeable battery 694 of the preferred embodiment, is shown in conjunction with
The operating power for the IPG 391R is derived from a rechargeable power source 694. The rechargeable power source 694 comprises a rechargeable lithium-ion or lithium-ion polymer battery. Recharging occurs inductively from an external charger to an implanted coil 48B underneath the skin 60. The rechargeable battery 694 may be recharged repeatedly as needed. Additionally, the IPG 391R is able to monitor and telemeter the status of its rechargable battery 691 each time a communication link is established with the external programmer 85.
Much of the circuitry included within the IPG 391R may be realized on a single application specific integrated circuit (ASIC). This allows the overall size of the IPG 391R to be quite small, and readily housed within a suitable hermetically-sealed case. The IPG case is preferably made from titanium and is shaped in a rounded case.
Shown in conjunction with
A simplified block diagram of charge completion and misalignment detection circuitry is shown in conjunction with
The indicator 706 may similarly be used as a misalignment indicator. In normal operation, when coils 46B (external) and 48B (implanted) are properly aligned, the voltage Vs sensed by voltage detector 704 is at a minimum level because maximum energy transfer is taking place. If and when the coils 46B and 48B become misaligned, then less than a maximum energy transfer occurs, and the voltage Vs sensed by detection circuit 704 increases significantly. If the voltage Vs reaches a predetermined level, alignment indicator 706 is activated via an audible speaker and/or LEDs for visual feedback. After adjustment, when an optimum energy transfer condition is established, causing Vs to decrease below the predetermined threshold level, the alignment indicator 706 is turned off.
The elements of the external recharger are shown as a block diagram in conjunction with
As also shown in
Referring now to
TABLE 3 Lead design variables Proximal Distal End End Conductor (connecting Lead body- proximal Lead Insulation and distal Electrode - Electrode - Terminal Materials Lead-Coating ends) Material Type Linear Polyurethane Antimicrobial Alloy of Pure Spiral bipolar coating Nickel- Platinum electrode Cobalt Bifurcated Silicone Anti- Platinum- Wrap-around Inflammatory Iridium electrode coating (Pt/Ir) Alloy Silicone with Lubricious Pt/Ir coated Steroid Polytetrafluoroethylene coating with Titanium eluting (PTFE) Nitride Carbon Hydrogel electrodes Cuff electrodes
Once the lead is fabricated, coating such as anti-microbial, anti-inflammatory, or lubricious coating may be applied to the body of the lead.
In one aspect of the invention, in addition to selective stimulation of the sympathetic system, selective portions of the nervous system may be blocked. Typically when a nerve pathway is stimulated, the stimulation is conducted in both the Afferent (towards the brain) and Efferent (away from the brain) direction. Shown in conjunction with
Selective Efferent block can also be obtained and is depicted in conjunction with
Blocking can be generally divided into 3 categories: (a) DC or anodal block, (b) Wedenski Block, and (c) Collision block. In anodal block there is a steady potential which is applied to the nerve causing a reversible and selective block. In Wedenski Block, the nerve is stimulated at a high rate causing the rapid depletion of the neurotransmitter. In collision blocking, unidirectional action potentials are generated anti-dromically. The maximal frequency for complete block is the reciprocal of the refractory period plus the transit time i.e. typically less than a few hundred hertz. The use of any of these blocking techniques is considered within the scope of this invention.
Shown in conjunction with
The telecommunications component of this invention uses Wireless Application Protocol (WAP). WAP is a set of communication protocols standardizing Internet access for wireless devices. Previously, manufacturers used different technologies to get Internet on hand-held devices. With WAP, devices and services inter-operate. WAP promotes convergence of wireless data and the Internet. The WAP Layers are Wireless Application Envirnment (WAEW), Wireless Session Layer (WSL), Wireless Transport Layer Security (WTLS) and Wireless Transport Layer (WTP).
The WAP programming model, which is heavily based on the existing Internet programming model, is shown schematically in
The key components of the WAP technology, as shown in
The presently preferred embodiment utilizes WAP, because WAP has the following advantages, 1) WAP protocol uses less than one-half the number of packets that the standard HTTP or TCP/IP Internet stack uses to deliver the same content. 2) Addressing the limited resources of the terminal, the browser, and the lightweight protocol stack are designed to make small claims on CPU and ROM. 3) Binary encoding of WML and SMLScript helps keep the RAM as small as possible. And, 4) Keeping the bearer utilization low takes account of the limited battery power of the terminal.
In this embodiment two modes of communication are possible. In the first, the server initiates an upload of the actual parameters being applied to the patient, receives these from the stimulator, and stores these in its memory, accessible to the authorized user as a dedicated content driven web page. The web page is managed with adequate security and password protection. The physician or authorized user can make alterations to the actual parameters, as available on the server, and then initiate a communication session with the stimulator device to download these parameters.
The physician is also able to set up long-term schedules of stimulation therapy for their patient population, through wireless communication with the server. The server in turn communicates these programs to the neurostimulator. Each schedule is securely maintained on the server, and is editable by the physician and can get uploaded to the patient's stimulator device at a scheduled time. Thus, therapy can be customized for each individual patient. Each device issued to a patient has a unique identification key in order to guarantee secure communication between the wireless server 130 and stimulator device 42 (or programmer 85).
Shown in conjunction with
The standard components of interface unit shown in block 292 are processor 305, storage 310, memory 308, transmitter/receiver 306, and a communication device such as network interface card or modem 312. In the preferred embodiment these components are embedded in the external stimulator 42 and can also be embedded in the programmer 85. These can be connected to the network 290 through appropriate security measures (Firewall) 293.
Another type of remote unit that may be accessed via central collaborative network 290 is remote computer 294. This remote computer 294 may be used by an appropriate attending physician to instruct or interact with interface unit 292, for example, instructing interface unit 292 to send instruction downloaded from central computer 286 to remote implanted unit.
Shown in conjunction with
The telemetry module 362 comprises an RF telemetry antenna 142 coupled to a telemetry transceiver and antenna driver circuit board which includes a telemetry transmitter and telemetry receiver. The telemetry transmitter and receiver are coupled to control circuitry and registers, operated under the control of microprocessor 364. Similarly, within stimulator a telemetry antenna 142 is coupled to a telemetry transceiver comprising RF telemetry transmitter and receiver circuit. This circuit is coupled to control circuitry and registers operated under the control of microcomputer circuit.
With reference to the telecommunications aspects of the invention, the communication and data exchange between Modified PDA/Phone 140 and external stimulator 42 operates on commercially available frequency bands. The 2.4-to-2.4853 GHz bands or 5.15 and 5.825 GHz, are the two unlicensed areas of the spectrum, and set aside for industrial, scientific, and medical (ISM) uses. Most of the technology today including this invention, use either the 2.4 or 5 GHz radio bands and spread-spectrum technology.
The telecommunications technology, especially the wireless internet technology, which this invention utilizes in one embodiment, is constantly improving and evolving at a rapid pace, due to advances in RF and chip technology as well as software development. Therefore, one of the intents of this invention is to utilize “state of the art” technology available for data communication between Modified PDA/Phone 140 and external stimulator 42. The intent of this invention is to use 3G technology for wireless communication and data exchange, even though in some cases 2.5G is being used currently.
For the system of the current invention, the use of any of the “3G” technologies for communication for the Modified PDA/Phone 140, is considered within the scope of the invention. Further, it will be evident to one of ordinary skill in the art that as future 4G systems, which will include new technologies such as improved modulation and smart antennas, can be easily incorporated into the system and method of current invention, and are also considered within the scope of the invention.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US5188104 *||Feb 1, 1991||Feb 23, 1993||Cyberonics, Inc.||Treatment of eating disorders by nerve stimulation|
|US5263480 *||Aug 7, 1992||Nov 23, 1993||Cyberonics, Inc.||Treatment of eating disorders by nerve stimulation|
|US5540730 *||Jun 6, 1995||Jul 30, 1996||Cyberonics, Inc.||Treatment of motility disorders by nerve stimulation|
|US5713939 *||Sep 16, 1996||Feb 3, 1998||Sulzer Intermedics Inc.||Data communication system for control of transcutaneous energy transmission to an implantable medical device|
|US6067474 *||Jul 31, 1998||May 23, 2000||Advanced Bionics Corporation||Implantable device with improved battery recharging and powering configuration|
|US6505077 *||Jun 19, 2000||Jan 7, 2003||Medtronic, Inc.||Implantable medical device with external recharging coil electrical connection|
|US6553263 *||Jul 28, 2000||Apr 22, 2003||Advanced Bionics Corporation||Implantable pulse generators using rechargeable zero-volt technology lithium-ion batteries|
|US6591137 *||Nov 9, 2000||Jul 8, 2003||Neuropace, Inc.||Implantable neuromuscular stimulator for the treatment of gastrointestinal disorders|
|US6611715 *||Apr 19, 2001||Aug 26, 2003||Birinder R. Boveja||Apparatus and method for neuromodulation therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator|
|US6622041 *||Aug 21, 2001||Sep 16, 2003||Cyberonics, Inc.||Treatment of congestive heart failure and autonomic cardiovascular drive disorders|
|US6650943 *||Mar 6, 2001||Nov 18, 2003||Advanced Bionics Corporation||Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction|
|US20030018367 *||Jul 19, 2002||Jan 23, 2003||Dilorenzo Daniel John||Method and apparatus for neuromodulation and phsyiologic modulation for the treatment of metabolic and neuropsychiatric disease|
|US20030036773 *||Aug 2, 2002||Feb 20, 2003||Whitehurst Todd K.||Systems and methods for treatment of coronary artery disease|
|US20030144708 *||May 17, 2002||Jul 31, 2003||Starkebaum Warren L.||Methods and apparatus for retarding stomach emptying for treatment of eating disorders|
|US20030181958 *||Sep 13, 2002||Sep 25, 2003||Dobak John D.||Electric modulation of sympathetic nervous system|
|US20030181959 *||Oct 16, 2002||Sep 25, 2003||Dobak John D.||Wireless electric modulation of sympathetic nervous system|
|US20030212440 *||Jul 16, 2002||Nov 13, 2003||Boveja Birinder R.||Method and system for modulating the vagus nerve (10th cranial nerve) using modulated electrical pulses with an inductively coupled stimulation system|
|US20050131486 *||Jan 31, 2005||Jun 16, 2005||Boveja Birinder R.||Method and system for vagal blocking with or without vagal stimulation to provide therapy for obesity and other gastrointestinal disorders using rechargeable implanted pulse generator|
|US20050143787 *||Jan 13, 2005||Jun 30, 2005||Boveja Birinder R.||Method and system for providing electrical pulses for neuromodulation of vagus nerve(s), using rechargeable implanted pulse generator|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7167750||Jan 6, 2004||Jan 23, 2007||Enteromedics, Inc.||Obesity treatment with electrically induced vagal down regulation|
|US7184839 *||Dec 16, 2002||Feb 27, 2007||Medtronic, Inc.||Catheter-delivered cardiac lead|
|US7236822 *||Oct 16, 2002||Jun 26, 2007||Leptos Biomedical, Inc.||Wireless electric modulation of sympathetic nervous system|
|US7239912 *||Sep 13, 2002||Jul 3, 2007||Leptos Biomedical, Inc.||Electric modulation of sympathetic nervous system|
|US7239918||Jun 10, 2005||Jul 3, 2007||Ndi Medical Inc.||Implantable pulse generator for providing functional and/or therapeutic stimulation of muscles and/or nerves and/or central nervous system tissue|
|US7283867||Jun 10, 2005||Oct 16, 2007||Ndi Medical, Llc||Implantable system and methods for acquisition and processing of electrical signals from muscles and/or nerves and/or central nervous system tissue|
|US7343202||Jun 10, 2005||Mar 11, 2008||Ndi Medical, Llc.||Method for affecting urinary function with electrode implantation in adipose tissue|
|US7444183||Jan 6, 2004||Oct 28, 2008||Enteromedics, Inc.||Intraluminal electrode apparatus and method|
|US7551964||Feb 24, 2004||Jun 23, 2009||Leptos Biomedical, Inc.||Splanchnic nerve stimulation for treatment of obesity|
|US7565198||Jun 10, 2005||Jul 21, 2009||Medtronic Urinary Solutions, Inc.||Systems and methods for bilateral stimulation of left and right branches of the dorsal genital nerves to treat dysfunctions, such as urinary incontinence|
|US7623924||Aug 30, 2005||Nov 24, 2009||Leptos Biomedical, Inc.||Devices and methods for gynecologic hormone modulation in mammals|
|US7672727||Aug 17, 2005||Mar 2, 2010||Enteromedics Inc.||Neural electrode treatment|
|US7689276||Aug 18, 2004||Mar 30, 2010||Leptos Biomedical, Inc.||Dynamic nerve stimulation for treatment of disorders|
|US7689277||Jan 24, 2006||Mar 30, 2010||Leptos Biomedical, Inc.||Neural stimulation for treatment of metabolic syndrome and type 2 diabetes|
|US7689284||Oct 12, 2005||Mar 30, 2010||Intrapace, Inc.||Pseudounipolar lead for stimulating a digestive organ|
|US7693577||Jan 22, 2007||Apr 6, 2010||Enteromedics Inc.||Irritable bowel syndrome treatment|
|US7702386||Jan 24, 2007||Apr 20, 2010||Leptos Biomedical, Inc.||Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes|
|US7702394||Sep 23, 2004||Apr 20, 2010||Intrapace, Inc.||Responsive gastric stimulator|
|US7711430||Nov 2, 2006||May 4, 2010||Electrocore Llc||Methods and apparatus for treating anaphylaxis using electrical modulation|
|US7720540||Jan 22, 2007||May 18, 2010||Enteromedics, Inc.||Pancreatitis treatment|
|US7725188||Nov 2, 2006||May 25, 2010||Electrocore Llc||Electrical stimulation treatment of hypotension|
|US7725195||Feb 16, 2007||May 25, 2010||Imthera Medical, Inc.||RFID-based apparatus, system, and method for therapeutic treatment of obstructive sleep apnea|
|US7729771||Aug 13, 2007||Jun 1, 2010||Enteromedics Inc.||Nerve stimulation and blocking for treatment of gastrointestinal disorders|
|US7738961||Oct 9, 2006||Jun 15, 2010||Endostim, Inc.||Method and apparatus for treatment of the gastrointestinal tract|
|US7747322||Oct 12, 2005||Jun 29, 2010||Intrapace, Inc.||Digestive organ retention device|
|US7747324||Nov 1, 2006||Jun 29, 2010||Electrocore Llc||Electrical stimulation treatment of bronchial constriction|
|US7756582||Oct 21, 2005||Jul 13, 2010||Intrapace, Inc.||Gastric stimulation anchor and method|
|US7761167||Oct 2, 2006||Jul 20, 2010||Medtronic Urinary Solutions, Inc.||Systems and methods for clinician control of stimulation systems|
|US7813809||Jun 10, 2005||Oct 12, 2010||Medtronic, Inc.||Implantable pulse generator for providing functional and/or therapeutic stimulation of muscles and/or nerves and/or central nervous system tissue|
|US7822486||Aug 17, 2005||Oct 26, 2010||Enteromedics Inc.||Custom sized neural electrodes|
|US7844338||Jun 30, 2004||Nov 30, 2010||Enteromedics Inc.||High frequency obesity treatment|
|US7869879||Jul 21, 2009||Jan 11, 2011||Electrocore Llc||Electrical stimulation treatment of hypotension|
|US7937144||May 17, 2007||May 3, 2011||Advanced Neuromodulation Systems, Inc.||Electric modulation of sympathetic nervous system|
|US7937145||Jun 11, 2007||May 3, 2011||Advanced Neuromodulation Systems, Inc.||Dynamic nerve stimulation employing frequency modulation|
|US7937159||Apr 1, 2010||May 3, 2011||Imthera Medical Inc.||Apparatus, system and method for therapeutic treatment of obstructive sleep apnea|
|US8010204||Mar 11, 2010||Aug 30, 2011||Enteromedics Inc.||Nerve blocking for treatment of gastrointestinal disorders|
|US8046085||Oct 25, 2011||Enteromedics Inc.||Controlled vagal blockage therapy|
|US8145299||Feb 12, 2010||Mar 27, 2012||Advanced Neuromodulation Systems, Inc.||Neural stimulation for treatment of metabolic syndrome and type 2 diabetes|
|US8160709||May 14, 2007||Apr 17, 2012||Endostim, Inc.||Use of electrical stimulation of the lower esophageal sphincter to modulate lower esophageal sphincter pressure|
|US8209034||Dec 18, 2008||Jun 26, 2012||Electrocore Llc||Methods and apparatus for electrical stimulation treatment using esophageal balloon and electrode|
|US8295926||Oct 23, 2009||Oct 23, 2012||Advanced Neuromodulation Systems, Inc.||Dynamic nerve stimulation in combination with other eating disorder treatment modalities|
|US8326426||Apr 3, 2009||Dec 4, 2012||Enteromedics, Inc.||Implantable device with heat storage|
|US8401650||Feb 27, 2009||Mar 19, 2013||Electrocore Llc||Methods and apparatus for electrical treatment using balloon and electrode|
|US8428725||Apr 23, 2013||Imthera Medical, Inc.||Method of stimulating a Hypoglossal nerve for controlling the position of a patient's tongue|
|US8447403||May 21, 2013||Endostim, Inc.||Device and implantation system for electrical stimulation of biological systems|
|US8447404||Mar 4, 2011||May 21, 2013||Endostim, Inc.||Device and implantation system for electrical stimulation of biological systems|
|US8538534||Mar 13, 2012||Sep 17, 2013||Endostim, Inc.||Systems and methods for electrically stimulating the lower esophageal sphincter to treat gastroesophageal reflux disease|
|US8538542||Jul 21, 2011||Sep 17, 2013||Enteromedics Inc.||Nerve stimulation and blocking for treatment of gastrointestinal disorders|
|US8543210||Jan 25, 2009||Sep 24, 2013||Endostim, Inc.||Device and implantation system for electrical stimulation of biological systems|
|US8543211||Jul 22, 2009||Sep 24, 2013||ElectroCore, LLC||Methods and apparatus for deep brain stimulation|
|US8612004||Jun 29, 2012||Dec 17, 2013||ElectroCore, LLC||Electrical stimulation treatment of hypotension|
|US8644921 *||May 16, 2011||Feb 4, 2014||Neurostream Technologies G. P.||Neuromodulation system and method for treating apnea|
|US8649870||Oct 31, 2007||Feb 11, 2014||Medtronic Uninary Solutions, Inc.||Systems and methods including lead and electrode structures sized and configured for implantation in adipose tissue|
|US8666496||Feb 17, 2013||Mar 4, 2014||ElectroCore, LLC||Methods and apparatus for electrical treatment using balloon and electrode|
|US8682449||Aug 27, 2009||Mar 25, 2014||ElectroCore, LLC||Methods and apparatus for transcranial stimulation|
|US8706252||Jul 1, 2010||Apr 22, 2014||Medtronic, Inc.||Systems and methods for clinician control of stimulation system|
|US8712529||Mar 4, 2011||Apr 29, 2014||Endostim, Inc.||Device and implantation system for electrical stimulation of biological systems|
|US8712530||Mar 4, 2011||Apr 29, 2014||Endostim, Inc.||Device and implantation system for electrical stimulation of biological systems|
|US8740895||Jun 28, 2013||Jun 3, 2014||Holaira, Inc.||Delivery devices with coolable energy emitting assemblies|
|US8751005||Mar 19, 2013||Jun 10, 2014||Imthera Medical, Inc.||Method of stimulating a hypoglossal nerve for controlling the position of a patients tongue|
|US8777943||Jun 28, 2013||Jul 15, 2014||Holaira, Inc.||Delivery devices with coolable energy emitting assemblies|
|US8798753||Jul 2, 2013||Aug 5, 2014||Endostim, Inc.||Device and implantation system for electrical stimulation of biological systems|
|US8838231||Jun 3, 2011||Sep 16, 2014||Advanced Neuromodulation Systems, Inc.||Neural Stimulation for treatment of metabolic syndrome and type 2 diabetes|
|US8840537||Feb 1, 2011||Sep 23, 2014||ElectroCore, LLC||Non-invasive treatment of bronchial constriction|
|US8911439||Nov 11, 2010||Dec 16, 2014||Holaira, Inc.||Non-invasive and minimally invasive denervation methods and systems for performing the same|
|US8929986||Nov 5, 2012||Jan 6, 2015||Nevro Corporation||Medical device communication and charging assemblies for use with implantable signal generators, and associated systems and methods|
|US8932289||Sep 26, 2011||Jan 13, 2015||Holaira, Inc.||Delivery devices with coolable energy emitting assemblies|
|US9005195||Sep 26, 2011||Apr 14, 2015||Holaira, Inc.||Delivery devices with coolable energy emitting assemblies|
|US9017324||Jun 28, 2013||Apr 28, 2015||Holaira, Inc.||Delivery devices with coolable energy emitting assemblies|
|US9037247||Aug 19, 2010||May 19, 2015||ElectroCore, LLC||Non-invasive treatment of bronchial constriction|
|US9061147||Mar 7, 2014||Jun 23, 2015||Endostim, Inc.||Device and implantation system for electrical stimulation of biological systems|
|US20040116993 *||Dec 16, 2002||Jun 17, 2004||Clemens William J.||Catheter-delivered cardiac lead|
|US20040167583 *||Jan 6, 2004||Aug 26, 2004||Enteromedics, Inc.||Electrode band apparatus and method|
|US20040172084 *||Feb 3, 2003||Sep 2, 2004||Knudson Mark B.||Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)|
|US20040172085 *||Sep 29, 2003||Sep 2, 2004||Beta Medical, Inc.||Nerve stimulation and conduction block therapy|
|US20040172086 *||Sep 29, 2003||Sep 2, 2004||Beta Medical, Inc.||Nerve conduction block treatment|
|US20040172088 *||Jan 6, 2004||Sep 2, 2004||Enteromedics, Inc.||Intraluminal electrode apparatus and method|
|US20040176812 *||Sep 29, 2003||Sep 9, 2004||Beta Medical, Inc.||Enteric rhythm management|
|US20040230255 *||Feb 24, 2004||Nov 18, 2004||Dobak John D.||Splanchnic nerve stimulation for treatment of obesity|
|US20050038484 *||Jun 30, 2004||Feb 17, 2005||Enteromedics, Inc.||Controlled vagal blockage therapy|
|US20050065571 *||Sep 23, 2004||Mar 24, 2005||Imran Mir A.||Responsive gastric stimulator|
|US20050065575 *||Aug 18, 2004||Mar 24, 2005||Dobak John D.||Dynamic nerve stimulation for treatment of disorders|
|US20050070970 *||Jan 12, 2004||Mar 31, 2005||Knudson Mark B.||Movement disorder stimulation with neural block|
|US20050070974 *||Jan 12, 2004||Mar 31, 2005||Knudson Mark B.||Obesity and eating disorder stimulation treatment with neural block|
|US20050131485 *||Jan 21, 2005||Jun 16, 2005||Enteromedics, Inc.||High frequency vagal blockage therapy|
|US20050143784 *||Nov 18, 2004||Jun 30, 2005||Imran Mir A.||Gastrointestinal anchor with optimal surface area|
|US20060004421 *||Jun 10, 2005||Jan 5, 2006||Bennett Maria E||Systems and methods for bilateral stimulation of left and right branches of the dorsal genital nerves to treat dysfunctions, such as urinary incontinence|
|US20060020298 *||Aug 23, 2004||Jan 26, 2006||Camilleri Michael L||Systems and methods for curbing appetite|
|US20120253249 *||Oct 4, 2012||Willard Wilson||Neuromodulation System and Method For Treating Apnea|
|USD736383||Nov 5, 2012||Aug 11, 2015||Nevro Corporation||Implantable signal generator|
|USD736930||Apr 5, 2013||Aug 18, 2015||Nevro Corporation||Implantable signal generator|
|EP2254462A1 *||Nov 12, 2008||Dec 1, 2010||Daniel J. Dilorenzo||Method and apparatus for programming of autonomic neuromodulation for the treatment of obesity|
|WO2004075974A2 *||Feb 24, 2004||Sep 10, 2004||John D Dobak Iii||Splanchnic nerve stimulation for treatment of obesity|
|WO2009064408A1 *||Nov 12, 2008||May 22, 2009||Daniel J Dilorenzo||Method and apparatus for programming of autonomic neuromodulation for the treatment of obesity|
|WO2010141481A1 *||Jun 1, 2010||Dec 9, 2010||Autonomic Technologies, Inc.||Methods and devices for adrenal stimulation|
|U.S. Classification||607/58, 607/46|
|International Classification||A61N1/362, A61N1/34, A61N1/40, A61N1/08, A61N1/36|
|Cooperative Classification||A61N1/40, A61N1/36071, A61N1/36114, A61N1/3627, A61N1/08, A61N1/36082, A61N1/36007|
|European Classification||A61N1/36Z, A61N1/36Z3C, A61N1/362C, A61N1/36B, A61N1/36Z3J, A61N1/36Z3E, A61N1/40, A61N1/08, A61N1/36|
|Sep 14, 2006||AS||Assignment|
Owner name: NEURO AND CARDIAC TECHNOLOGIES, LLC, WISCONSIN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOVEJA, BIRINDER R.;WIDHANY, ANGELY;REEL/FRAME:018728/0352;SIGNING DATES FROM 20060911 TO 20060914